Overview

JAK Inhibitor Treatment in AGS

Status:
Active, not recruiting

Trial end date:
2025-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to assess safety as well as efficacy of baricitinib, a Janus Kinase (JAK) inhibitor, in patients with Aicardi Goutières Syndrome (AGS), a multisystem heritable disorder of the innate immunity resulting in excessive interferon production

Phase:

Phase 2

Details

Lead Sponsor:

Adeline Vanderver, MD

Collaborator:

Eli Lilly and Company

Treatments:

Janus Kinase Inhibitors